Pulmonary disease, chronic obstructive Trials in Marburg, Germany
Conditions / Pulmonary disease, chronic obstructive / Marburg, Germany
Research into Pulmonary disease, chronic obstructive spans multiple therapeutic approaches and trial phases.
19 total trials for this combination
Showing top 10 of 19 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT02296138 | Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. | COMPLETED | PHASE3 |
| NCT01126437 | Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT01017952 | A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT00528996 | An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. | COMPLETED | PHASE2 |
| NCT04072887 | Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients | COMPLETED | PHASE2 |
| NCT02164513 | A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT00975195 | Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE4 |
| NCT03034915 | A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE4 |
| NCT00563381 | Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients. | COMPLETED | PHASE4 |